دورية أكاديمية
Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.
| العنوان: | Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study. |
|---|---|
| المؤلفون: | Thieblemont, Catherine, Howlett, S., Casasnovas, R. O., Mounier, N., Perrot, A., Morschhauser, Franck, Fruchart, C., Daguindau, N., van Eygen, K., Obéric, L., Bouabdallah, R., Pica, G. M., Nicolas-Virezelier, E., Abraham, J., Fitoussi, O., Snauwaert, S., Eisenmann, J. C., Lionne-Huyghe, P., Bron, D., Tricot, S., Deeren, D., Gonzalez, H., Costello, R., Le Du, K., da Silva, M. G., Grosicki, S., Trotman, J., Catalano, J., Caballero, D., Greil, R., Cohen, A. M., Gaulard, P., Roulin, L., Takeshita, K., Casadebaig, M. L., Tilly, H., Coiffier, B. |
| المساهمون: | Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille) |
| المصدر: | ISSN: 0007-1048. |
| بيانات النشر: | HAL CCSD Wiley |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | therapy, quality of life, non-Hodgkin lymphoma, [SDV]Life Sciences [q-bio] |
| الوصف: | International audience ; Lenalidomide maintenance therapy prolonged progression-free survival (PFS) versus placebo in elderly patients with diffuse large B-cell lymphoma (DLBCL) responding to induction chemotherapy in the phase 3 REMARC study. This subpopulation analysis assessed the impact of lenalidomide maintenance and treatment-emergent adverse events (TEAEs) on health-related quality of life (HRQOL). Global health status (GHS), and physical functioning and fatigue subscales were evaluated in patients who completed the European Organisation for Research and Treatment of Cancer quality-of-life questionnaire-C30 v3.0. The impact of TEAEs classified post hoc as subjective (patients can feel) or observable (only measurable by physicians) on dose reductions and discontinuations was assessed. Among 457 patients (lenalidomide, n = 229; placebo, n = 228), mean (standard deviation) GHS was similar between treatment arms [68·2 (20·7) Versus 72·0 (17·8)] at randomisation and remained similar during maintenance. Patients receiving lenalidomide experienced no meaningful changes in GHS, physical functioning, or fatigue. Observable TEAEs were more common (81·1% Versus 66·3%) and more likely to lead to dose reductions, than subjective TEAEs in both arms. PFS was superior in the lenalidomide arm regardless of dose reduction. Lenalidomide maintenance prolonged PFS and did not negatively impact HRQOL in patients with DLBCL despite TEAEs being more common, when compared with placebo. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/31702836; hal-04219542; https://hal.univ-lille.fr/hal-04219542Test; https://hal.univ-lille.fr/hal-04219542/documentTest; https://hal.univ-lille.fr/hal-04219542/file/Br%20J%20Haematol%20-%202019%20-%20Thieblemont.pdfTest; PUBMED: 31702836 |
| DOI: | 10.1111/bjh.16300 |
| الإتاحة: | https://doi.org/10.1111/bjh.16300Test https://hal.univ-lille.fr/hal-04219542Test https://hal.univ-lille.fr/hal-04219542/documentTest https://hal.univ-lille.fr/hal-04219542/file/Br%20J%20Haematol%20-%202019%20-%20Thieblemont.pdfTest |
| حقوق: | http://creativecommons.org/licenses/by-ncTest/ ; info:eu-repo/semantics/OpenAccess |
| رقم الانضمام: | edsbas.26E964D7 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1111/bjh.16300 |
|---|